Add Ezetimibe as the Next Drug
In a patient with prior ischemic stroke whose LDL-C remains at 90 mg/dL on rosuvastatin 10 mg, add ezetimibe 10 mg daily before increasing the statin dose. 1
Rationale Based on Guidelines
The 2021 AHA/ASA Stroke Prevention Guideline explicitly states that when LDL-C remains ≥70 mg/dL on maximally tolerated statin therapy, it is reasonable to add ezetimibe first, then consider a PCSK9 inhibitor if necessary in very high-risk patients 1. The 2018 AHA/ACC Cholesterol Guideline reinforces this sequential approach: ezetimibe should be added to statin therapy when LDL-C stays ≥70 mg/dL in very high-risk ASCVD patients 2.
Your patient qualifies as very high-risk because they have a history of ischemic stroke (a major ASCVD event) 1, 2. This classification triggers the LDL-C threshold of 70 mg/dL for considering additional therapy beyond statins.
Why Ezetimibe Before Dose Escalation
The TST trial specifically demonstrated that ezetimibe as second-line therapy achieved an LDL-C target of <70 mg/dL in stroke patients 1. This evidence directly supports using ezetimibe before PCSK9 inhibitors in the ischemic stroke population.
Practical advantages of adding ezetimibe:
- Provides an additional 15-25% LDL-C reduction when added to statins 1
- From your patient's baseline of 90 mg/dL, ezetimibe addition should bring LDL-C to approximately 65-75 mg/dL
- Better tolerated than high-intensity statin escalation
- More cost-effective than PCSK9 inhibitors
- Network meta-analysis shows ezetimibe plus statins superior to statin monotherapy for preventing recurrent stroke (RR 0.62) 3
The Sequential Algorithm
Step 1: Confirm the patient is on maximally tolerated statin therapy
- Rosuvastatin 10 mg is moderate-intensity; you could increase to 20 mg (high-intensity) 1
- However, guidelines prioritize adding ezetimibe over dose escalation when LDL-C ≥70 mg/dL
Step 2: Add ezetimibe 10 mg daily 1, 2
- Recheck LDL-C in 4-12 weeks 1
Step 3: If LDL-C remains ≥70 mg/dL on statin plus ezetimibe, consider PCSK9 inhibitor 1, 2
- This applies particularly if additional high-risk conditions exist (age ≥65, diabetes, hypertension, CKD, smoking) 1
Common Pitfalls to Avoid
Don't reflexively increase statin dose first. While rosuvastatin 20 mg provides greater LDL-C reduction than 10 mg, the guideline-directed approach for patients already on statins with LDL-C ≥70 mg/dL is to add non-statin therapy 1. Increasing from rosuvastatin 10 to 20 mg adds myopathy risk without the proven stroke-specific benefit demonstrated for combination therapy 4.
Don't skip ezetimibe and jump to PCSK9 inhibitors. The sequential approach (statin → add ezetimibe → add PCSK9 inhibitor if needed) is explicitly recommended 1. Real-world data shows only 3.6-5.1% of stroke patients receive combination therapy, representing a major treatment gap 5.
Don't delay treatment. Only 42-50% of stroke patients achieve LDL-C <70 mg/dL in real-world practice 5. Early intensification matters—recent observational data shows switching to rosuvastatin plus ezetimibe achieved target LDL-C <70 mg/dL in 71% of stroke patients at 6 months 6.
Addressing Hemorrhagic Stroke Concerns
A legitimate concern is whether aggressive LDL-C lowering increases hemorrhagic stroke risk. The SPARCL trial showed a small increase in hemorrhagic stroke with atorvastatin 80 mg 1, and meta-analysis confirms statin monotherapy carries this risk (RR 1.57) 3. However, ezetimibe plus statin combination does not increase hemorrhagic stroke risk compared to placebo 3, 7. This makes combination therapy particularly attractive—you achieve better ischemic stroke prevention without compounding hemorrhagic risk.
If Additional Risk Factors Present
Assess whether your patient has additional high-risk conditions that would make them "very high-risk" beyond just the stroke history 1:
- Age ≥65 years
- Diabetes mellitus
- Hypertension
- Chronic kidney disease (eGFR 15-59)
- Current smoking
- Prior coronary revascularization
If multiple high-risk conditions exist and LDL-C remains ≥70 mg/dL after adding ezetimibe, proceed directly to PCSK9 inhibitor (evolocumab or alirocumab) 1, 2. These agents provide an additional 50-60% LDL-C reduction and reduce ischemic stroke without increasing hemorrhagic stroke, even at very low achieved LDL-C levels 7.